IDDF2023-ABS-0145 HBeAg negative chronic hepatitis B patients with normal ALT and positive HBV DNA can benefit from nucleos(t)ide analogue therapy: results of a single center retrospective study with long-term follow-up

BackgroundThe clinical data on the outcomes of nucleos(t)ide analogues (NAs) therapy remains absent in HBeAg-negative patients with normal ALT and detectable HBV DNA. This study aimed to determine the efficacy of NAs treatment and the improvement of disease progression in this population.MethodsThis is a single-center retrospective study. The primary endpoint was the virological response (HBV DNA